×
About 3,630 results

ALLMedicine™ Apolipoprotein B Center

Research & Reviews  1,119 results

Local ablation of gastric cancer by reconstituted apolipoprotein B lipoparticles carryi...
https://doi.org/10.1016/j.nano.2021.102450
Nanomedicine : Nanotechnology, Biology, and Medicine; Yang CL, Chao YJ et. al.

Aug 1st, 2021 - Epigenetic inhibitors have shown anticancer effects. Combination chemotherapy with epigenetic inhibitors has shown high effectiveness in gastric cancer clinical trials, but severe side effect and local progression are the causes of treatment failu...

Serum apolipoprotein B/apolipoprotein A1 ratio in relation to intervertebral disk herni...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320064
Lipids in Health and Disease; Chen F, Wu T et. al.

Jul 31st, 2021 - This was a cross-sectional frequency-matched case-control study. The serum lipid profile of lipoprotein(a) [Lp(a)] level and apolipoprotein B/apolipoprotein A1 ratio (Apo B/Apo A1) ratio were found to be more representative for serum lipid level a...

Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in midd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320094
Lipids in Health and Disease; Qu G, Zhang Z et. al.

Jul 31st, 2021 - Discordance of lipid parameters is closely associated with residual cardiovascular risk. This study investigated the discordance between non-high-density lipoprotein cholesterol (non-HDL-C) or apolipoprotein B (apoB) and low-density lipoprotein ch...

Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prev...
https://doi.org/10.1093/eurheartj/ehab432
European Heart Journal; Quispe R, Martin SS et. al.

Jul 23rd, 2021 - Emerging evidence suggests that remnant cholesterol (RC) promotes atherosclerotic cardiovascular disease (ASCVD). We aimed to estimate RC-related risk beyond low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) in patients witho...

Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in chi...
https://doi.org/10.1111/obr.13312
Obesity Reviews : an Official Journal of the Internationa... Pluimakers VG, van Santen SS et. al.

Jul 15th, 2021 - Childhood cancer survivors (CCS) are at increased risk to develop metabolic syndrome (MetS), diabetes, and cardiovascular disease. Common criteria underestimate adiposity and possibly underdiagnose MetS, particularly after abdominal radiotherapy. ...

see more →

Guidelines  3 results

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL...
https://doi.org/10.1373/clinchem.2012.196733
Clinical Chemistry; , Cole TG et. al.

Feb 7th, 2013 - The number of circulating LDL particles is a strong indicator of future cardiovascular disease (CVD) events, even superior to the concentration of LDL cholesterol. Atherogenic (primarily LDL) particle number is typically determined either directly...

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipo...
https://doi.org/10.1373/clinchem.2008.118356
Clinical Chemistry; Contois JH, McConnell JP et. al.

Jan 27th, 2009 - Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years. Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (L...

see more →

Drugs  212 results see all →

Clinicaltrials.gov  33 results

Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
https://clinicaltrials.gov/ct2/show/NCT02591836

Apr 9th, 2020 - The primary purpose of this placebo-controlled study is to evaluate the low‐density lipoprotein cholesterol (LDL‐C) efficacy and dose‐response of gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination with atorvastatin 10,...

Antipsychotics and Blood Vessel Function
https://clinicaltrials.gov/ct2/show/NCT00585273

Aug 29th, 2019 - Participants will have all evaluations related to metabolic complications performed in the University of Iowa Clinical Research Unit (CRU) or in the EndoPAT laboratory located in Room 269 GH. For all visits, weights will be measured without shoes,...

Possible Links Between Inflammation and Lipid Metabolism
https://clinicaltrials.gov/ct2/show/NCT03392701

Oct 17th, 2018 - Sepsis is a severe clinical syndrome with still limited means of therapy and often poor prognosis. It has been recognized lately that sepsis and inflammation has an important impact on lipid metabolism and that the extent of hypocholesterolemia ma...

The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk
https://clinicaltrials.gov/ct2/show/NCT02770872

Mar 29th, 2018 - Cardiovascular disease (CVD) is the leading cause of death in developed nations and a major health issue in Veterans. Despite a number of different treatments, cardiovascular disease remains a major health burden, thus further treatments are neede...

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT01016730

Feb 20th, 2018 - PRIMARY OBJECTIVES: I. Estimate the maximum tolerated dose (MTD) of single agent bortezomib in subjects with AIDS-related Kaposi sarcoma (KS). SECONDARY OBJECTIVES: I. Evaluate the clinical response of KS tumors to bortezomib. II. Evaluate the imp...

see more →

News  85 results

LDL Not the Primary Culprit in ASCVD?
https://www.medscape.com/viewarticle/942629

Dec 14th, 2020 - Two new studies suggest that low-density lipoprotein cholesterol (LDL-C) may be not the main driver of atherosclerotic cardiovascular disease (ASCVD). The findings instead implicate remnant cholesterol (remnant-C) and very low-density lipoprotein ...

STRENGTH Trial Questions CV Benefit of High-Dose Omega-3s
https://www.medscape.com/viewarticle/941018

Nov 15th, 2020 - Questions about the cardiovascular benefit of omega-3 fatty acids and the high-dose eicosapentaenoic acid (EPA) product, icosapent ethyl (Vascepa, Amarin), have resurfaced with the presentation and publication of the STRENGTH trial using a combine...

Lipid Ratio Rules Out Pancreatitis Risk in Hypertriglyceridemia
https://www.medscape.com/viewarticle/939205

Oct 15th, 2020 - Calculating the ratio between serum triglyceride and apolipoprotein B levels may help rule out patients with hypertriglyceridemia who are at low risk of developing hypertriglyceridemic pancreatitis (HTGP), and so better guide management, suggests ...

Lipid Ratio Rules Out Pancreatitis Risk in Hypertriglyceridemia
https://www.staging.medscape.com/viewarticle/939205

Oct 15th, 2020 - Calculating the ratio between serum triglyceride and apolipoprotein B levels may help rule out patients with hypertriglyceridemia who are at low risk of developing hypertriglyceridemic pancreatitis (HTGP), and so better guide management, suggests ...

Depression or Anxiety? Metabolic Blood Biomarkers May Tell the Tale
https://www.medscape.com/viewarticle/938079

Sep 25th, 2020 - Metabolic alterations linked to inflammation and lipid metabolism can distinguish depression from anxiety and determine disease severity, new research suggests.  Results from a Dutch study included 1400 participants with anxiety, depression, or bo...

see more →